These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

336 related articles for article (PubMed ID: 11251019)

  • 1. 2000 update of recommendations for the use of tumor markers in breast and colorectal cancer: clinical practice guidelines of the American Society of Clinical Oncology.
    Bast RC; Ravdin P; Hayes DF; Bates S; Fritsche H; Jessup JM; Kemeny N; Locker GY; Mennel RG; Somerfield MR;
    J Clin Oncol; 2001 Mar; 19(6):1865-78. PubMed ID: 11251019
    [TBL] [Abstract][Full Text] [Related]  

  • 2. 1997 update of recommendations for the use of tumor markers in breast and colorectal cancer. Adopted on November 7, 1997 by the American Society of Clinical Oncology.
    J Clin Oncol; 1998 Feb; 16(2):793-5. PubMed ID: 9469371
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Clinical practice guidelines for the use of tumor markers in breast and colorectal cancer. Adopted on May 17, 1996 by the American Society of Clinical Oncology.
    J Clin Oncol; 1996 Oct; 14(10):2843-77. PubMed ID: 8874347
    [TBL] [Abstract][Full Text] [Related]  

  • 4. American Society of Clinical Oncology 1998 update of recommended breast cancer surveillance guidelines.
    Smith TJ; Davidson NE; Schapira DV; Grunfeld E; Muss HB; Vogel VG; Somerfield MR
    J Clin Oncol; 1999 Mar; 17(3):1080-2. PubMed ID: 10071303
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Recommended breast cancer surveillance guidelines. American Society of Clinical Oncology.
    J Clin Oncol; 1997 May; 15(5):2149-56. PubMed ID: 9164230
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Recommended colorectal cancer surveillance guidelines by the American Society of Clinical Oncology.
    Desch CE; Benson AB; Smith TJ; Flynn PJ; Krause C; Loprinzi CL; Minsky BD; Petrelli NJ; Pfister DG; Somerfield MR
    J Clin Oncol; 1999 Apr; 17(4):1312. PubMed ID: 10561194
    [TBL] [Abstract][Full Text] [Related]  

  • 7. American Society of Clinical Oncology 2007 update of recommendations for the use of tumor markers in breast cancer.
    Harris L; Fritsche H; Mennel R; Norton L; Ravdin P; Taube S; Somerfield MR; Hayes DF; Bast RC;
    J Clin Oncol; 2007 Nov; 25(33):5287-312. PubMed ID: 17954709
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Serum cytokeratin fragment 21.1 (CYFRA 21.1) as tumour marker for breast cancer: comparison with carbohydrate antigen 15.3 (CA 15.3) and carcinoembryonic antigen (CEA).
    Giovanella L; Ceriani L; Giardina G; Bardelli D; Tanzi F; Garancini S
    Clin Chem Lab Med; 2002 Mar; 40(3):298-303. PubMed ID: 12005221
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Clinical practice guidelines for the treatment of unresectable non-small-cell lung cancer. Adopted on May 16, 1997 by the American Society of Clinical Oncology.
    J Clin Oncol; 1997 Aug; 15(8):2996-3018. PubMed ID: 9256144
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Outcomes of cancer treatment for technology assessment and cancer treatment guidelines. American Society of Clinical Oncology.
    J Clin Oncol; 1996 Feb; 14(2):671-9. PubMed ID: 8636786
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Postmastectomy radiotherapy: clinical practice guidelines of the American Society of Clinical Oncology.
    Recht A; Edge SB; Solin LJ; Robinson DS; Estabrook A; Fine RE; Fleming GF; Formenti S; Hudis C; Kirshner JJ; Krause DA; Kuske RR; Langer AS; Sledge GW; Whelan TJ; Pfister DG;
    J Clin Oncol; 2001 Mar; 19(5):1539-69. PubMed ID: 11230499
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Standards, options and recommendations for tumor markers in colorectal cancer].
    Eche N; Pichon MF; Quillien V; Gory-Delabaere G; Riedinger JM; Basuyau JP; Daver A; Buecher B; Conroy T; Dieu L; Bidart JM; Deneux L;
    Bull Cancer; 2001 Dec; 88(12):1177-206. PubMed ID: 11792611
    [TBL] [Abstract][Full Text] [Related]  

  • 13. American Society of Clinical Oncology guideline on the role of bisphosphonates in breast cancer. American Society of Clinical Oncology Bisphosphonates Expert Panel.
    Hillner BE; Ingle JN; Berenson JR; Janjan NA; Albain KS; Lipton A; Yee G; Biermann JS; Chlebowski RT; Pfister DG
    J Clin Oncol; 2000 Mar; 18(6):1378-91. PubMed ID: 10715310
    [TBL] [Abstract][Full Text] [Related]  

  • 14. American Society of Clinical Oncology technology assessment on breast cancer risk reduction strategies: tamoxifen and raloxifene.
    Chlebowski RT; Collyar DE; Somerfield MR; Pfister DG
    J Clin Oncol; 1999 Jun; 17(6):1939-55. PubMed ID: 10561236
    [TBL] [Abstract][Full Text] [Related]  

  • 15. National Academy of Clinical Biochemistry laboratory medicine practice guidelines for use of tumor markers in testicular, prostate, colorectal, breast, and ovarian cancers.
    Sturgeon CM; Duffy MJ; Stenman UH; Lilja H; Brünner N; Chan DW; Babaian R; Bast RC; Dowell B; Esteva FJ; Haglund C; Harbeck N; Hayes DF; Holten-Andersen M; Klee GG; Lamerz R; Looijenga LH; Molina R; Nielsen HJ; Rittenhouse H; Semjonow A; Shih IeM; Sibley P; Sölétormos G; Stephan C; Sokoll L; Hoffman BR; Diamandis EP;
    Clin Chem; 2008 Dec; 54(12):e11-79. PubMed ID: 19042984
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Community compliance with carcinoembryonic antigen: follow-up of patients with colorectal cancer.
    Spratlin JL; Hui D; Hanson J; Butts C; Au HJ
    Clin Colorectal Cancer; 2008 Mar; 7(2):118-25. PubMed ID: 18501071
    [TBL] [Abstract][Full Text] [Related]  

  • 17. American Society of Clinical Oncology technology assessment of pharmacologic interventions for breast cancer risk reduction including tamoxifen, raloxifene, and aromatase inhibition.
    Chlebowski RT; Col N; Winer EP; Collyar DE; Cummings SR; Vogel VG; Burstein HJ; Eisen A; Lipkus I; Pfister DG;
    J Clin Oncol; 2002 Aug; 20(15):3328-43. PubMed ID: 12149307
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Promoting quality and evidence-based care in early-stage breast cancer follow-up.
    Henry NL; Hayes DF; Ramsey SD; Hortobagyi GN; Barlow WE; Gralow JR
    J Natl Cancer Inst; 2014 Apr; 106(4):dju034. PubMed ID: 24627271
    [TBL] [Abstract][Full Text] [Related]  

  • 19. CEA monitoring in colorectal cancer. What you should know.
    Fakih MG; Padmanabhan A
    Oncology (Williston Park); 2006 May; 20(6):579-87; discussion 588, 594, 596 passim. PubMed ID: 16773844
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Clinical cancer advances 2011: Annual Report on Progress Against Cancer from the American Society of Clinical Oncology.
    Vogelzang NJ; Benowitz SI; Adams S; Aghajanian C; Chang SM; Dreyer ZE; Janne PA; Ko AH; Masters GA; Odenike O; Patel JD; Roth BJ; Samlowski WE; Seidman AD; Tap WD; Temel JS; Von Roenn JH; Kris MG
    J Clin Oncol; 2012 Jan; 30(1):88-109. PubMed ID: 22147736
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 17.